Prophylactic efficacy of misoprostol against piroxicam and ampiroxicam induced gastroduodenal mucosal lesions.

概要

論文の詳細を見る
The effect of misoprostol (Cytotec<SUP>®</SUP>), an cytoprotective agent, in preventing mucosal damage caused by piroxicam and ampiroxicam was evaluated in 20 patients requiring NSAID. Patients with normal endoscopic findings were administered both misoprostol 600μg and ampiroxicam 27 mg for 2 weeks. Gastroduodenal mucosal damage was significantly less in the misoprostol administered group than the only ampiroxicam administered group (p<0.05) . There was a significantly lower incidence of development of gastroduodenal mucosal damage in the non-habit of drinking group than the group of habit of drinking. As to the preferential site for the development of thesee lesions, the commonest site was the duodenum. Against lesions developed in the duodenal, significantly higher prophylactic effect was observed for the misoprostol administered group.<BR>It is considered from these results that misoprostol exists a highly prophylactic effect against piroxicam and ampiroxicam induced upper gastrointestinal mucosal damage.
日本炎症・再生医学会の論文